Editorial: Metabolic associated fatty liver disease: clinical perspectives from pathogenesis to diagnosis and treatment.
作者信息
Huang Zhe, Ye Dewei, Loomes Kerry, Cheng Kenneth Kingyip, Hui Hannah Xiaoyan
机构信息
Department of Genetics and Developmental Science, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
Key Laboratory of Metabolic Phenotyping in Model Animals, Guangdong Pharmaceutical University, Guangzhou, China.
出版信息
Front Endocrinol (Lausanne). 2023 Jun 30;14:1206642. doi: 10.3389/fendo.2023.1206642. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Metabolic associated fatty liver disease: clinical perspectives from pathogenesis to diagnosis and treatment.社论：代谢相关脂肪性肝病：从发病机制到诊断与治疗的临床视角
Front Endocrinol (Lausanne). 2023 Jun 30;14:1206642. doi: 10.3389/fendo.2023.1206642. eCollection 2023.
2
Identification of Hepatic Dendritic Cells in Liver Biopsies Showing Steatosis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Associated with Obesity.鉴定代谢相关脂肪性肝病（MAFLD）相关肥胖患者肝活检组织中脂肪变性时的肝树突状细胞。
Med Sci Monit. 2022 Aug 8;28:e937528. doi: 10.12659/MSM.937528.
3
Clinical diagnosis, evaluation and treatment of liver disease in in alcoholics.酒精性肝病的临床诊断、评估及治疗
Fed Proc. 1967 Sep;26(5):1474-81.
4
Fatty liver with metabolic disorder, such as metabolic dysfunction-associated fatty liver disease, indicates high risk for developing diabetes mellitus.代谢紊乱相关的脂肪肝，如代谢功能障碍相关脂肪性肝病，提示其发生糖尿病的风险较高。
J Diabetes Investig. 2022 Jul;13(7):1245-1252. doi: 10.1111/jdi.13772. Epub 2022 Feb 28.
5
Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?代谢相关性脂肪性肝病病理生理学的当前观点：巨噬细胞是否是治疗的可行靶点？
Expert Rev Gastroenterol Hepatol. 2021 Jan;15(1):51-64. doi: 10.1080/17474124.2020.1817740. Epub 2020 Sep 17.
6
Nontransplant alternatives for the treatment of patients with metabolic disease.代谢性疾病患者治疗的非移植替代方案。
Semin Liver Dis. 1998;18(3):255-61. doi: 10.1055/s-2007-1007161.
7
Sleep Factors in Relation to Metabolic Dysfunction-Associated Fatty Liver Disease in Middle-Aged and Elderly Chinese.睡眠因素与中老年中国人代谢功能障碍相关脂肪性肝病的关系。
J Clin Endocrinol Metab. 2022 Sep 28;107(10):2874-2882. doi: 10.1210/clinem/dgac428.
8
Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.代谢相关脂肪性肝病各亚型在中年人群中的长期心血管结局存在差异。
Hepatol Int. 2022 Dec;16(6):1308-1317. doi: 10.1007/s12072-022-10407-7. Epub 2022 Sep 7.
9
Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease.代谢因素对非糖尿病代谢相关脂肪性肝病患者心血管疾病风险的影响。
Hepatol Int. 2023 Jun;17(3):626-635. doi: 10.1007/s12072-023-10517-w. Epub 2023 Apr 17.
10
Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.代谢相关脂肪性肝病：新命名及其影响。
World J Gastroenterol. 2023 Jan 21;29(3):549-560. doi: 10.3748/wjg.v29.i3.549.
引用本文的文献
1
Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project.机器学习识别代谢相关脂肪性肝病（MASLD）合并糖代谢异常的糖尿病患者心力衰竭的危险因素：西里西亚糖尿病-心脏研究。
Cardiovasc Diabetol. 2023 Nov 20;22(1):318. doi: 10.1186/s12933-023-02014-z.
本文引用的文献
1
Hepatic MDM2 Causes Metabolic Associated Fatty Liver Disease by Blocking Triglyceride-VLDL Secretion via ApoB Degradation.肝 MDM2 通过降解 ApoB 阻断甘油三酯-VLDL 分泌引起代谢相关脂肪性肝病。
Adv Sci (Weinh). 2022 Jul;9(20):e2200742. doi: 10.1002/advs.202200742. Epub 2022 May 7.
2
Nonalcoholic Fatty Liver Disease and Recent Guideline Updates.非酒精性脂肪性肝病与近期指南更新
Clin Liver Dis (Hoboken). 2021 Feb 1;17(1):23-28. doi: 10.1002/cld.1045. eCollection 2021 Jan.
3
An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase.非酒精性脂肪性肝病中脂质代谢失调概述，特别关注溶酶体酸性脂肪酶。
Am J Physiol Gastrointest Liver Physiol. 2020 Oct 1;319(4):G469-G480. doi: 10.1152/ajpgi.00049.2020. Epub 2020 Aug 19.
4
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.代谢相关脂肪性肝病新定义：国际专家共识声明。
J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8.
5
Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease.内质网应激信号与非酒精性脂肪性肝病发病机制。
J Hepatol. 2018 Oct;69(4):927-947. doi: 10.1016/j.jhep.2018.06.008. Epub 2018 Jun 27.
6
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎的病因、发病机制及治疗
N Engl J Med. 2017 Nov 23;377(21):2063-2072. doi: 10.1056/NEJMra1503519.
7
Fighting the fatty liver.对抗脂肪肝
Nature. 2017 Oct 11;550(7675):S102-S103. doi: 10.1038/550S102a.
8
New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD).深入探讨器官间串扰在非酒精性脂肪性肝病（NAFLD）发病机制中的作用。
Protein Cell. 2018 Feb;9(2):164-177. doi: 10.1007/s13238-017-0436-0. Epub 2017 Jun 22.
9
Cellular senescence drives age-dependent hepatic steatosis.细胞衰老导致与年龄相关的肝脂肪变性。
Nat Commun. 2017 Jun 13;8:15691. doi: 10.1038/ncomms15691.
10
Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A post hoc analysis of a cohort study.非超重非酒精性脂肪性肝病与心血管疾病的发生：一项队列研究的事后分析
Medicine (Baltimore). 2017 May;96(18):e6712. doi: 10.1097/MD.0000000000006712.
Zotero 插件